logo
Twitter
Discord
Email
logo
Tenaya Therapeutics, Inc.

Tenaya Therapeutics, Inc.

NASDAQ•TNYA
CEO: Mr. Faraz Ali M.B.A.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2021-07-30
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Contact Information
171 Oyster Point Boulevard, Suite 500, South San Francisco, CA, 94080, United States
650-825-6990
www.tenayatherapeutics.com
Market Cap
$121.54M
P/E (TTM)
-1.3
38.2
Dividend Yield
--
52W High
$2.35
52W Low
$0.36
52W Range
19%
Rank59Top 87.6%
2.2
F-Score
Modified Piotroski Analysis
Based on 6-year fundamentals
Weak • 2.2 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2020-2025

Financial Dashboard

Q3 2025 Data

Revenue

$0.00+0.00%
4-Quarter Trend

EPS

-$0.12-60.00%
4-Quarter Trend

FCF

-$15.63M-21.95%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

R&D Expenses Reduced 21% Nine-month R&D expenses totaled $53.8M, down $14.2M (21%) driven by workforce reduction cost containment measures.
Net Loss Narrows Significantly Nine-month net loss was $70.4M, improving by $16.9M (19%) compared to the prior year period due to expense control.
Cash Position Maintained Cash, equivalents, and investments stood at $56.3M as of September 30, 2025, supported by $50.2M financing proceeds.
TN-201 Trial Progress Positive MyPEAK-1 trial completed enrollment; DSMB endorsed expansion cohorts after reviewing acceptable safety profile data for TN-201.

Risk Factors

Substantial Future Capital Required Incurred accumulated deficit of $584.8M; requires substantial additional capital to fund operations beyond the next twelve months.
TN-201 Clinical Hold Issued FDA placed MyPEAK-1 on clinical hold requesting protocol amendment; working swiftly to resolve, but delays are possible.
Early Stage Unproven Therapies No products approved for sale; development remains lengthy, expensive, and highly uncertain regarding safety and efficacy outcomes.
Workforce Reduction Risks 2025 Workforce Reduction may cause attrition, loss of knowledge, and hinder ability to attract and retain critical personnel.

Outlook

Prioritize Lead Clinical Data Focus remains on generating data from TN-201 (MyPEAK-1) and TN-401 (RIDGE-1) clinical trials over the next twelve months.
Finalizing Cost Containment Expect substantially all remaining 2025 Workforce Reduction charges to be recognized by the end of the first quarter of 2026.
TN-301 Out-license Strategy Strategy for TN-301 (HDAC6 inhibitor) involves seeking out-license or partnership opportunities with well-resourced third parties.
Cash Runway Assessment Current cash plus loan availability expected to fund operations for at least the next twelve months following filing date.

Peer Comparison

Revenue (TTM)

Vanda Pharmaceuticals Inc.VNDA
$212.07M
+11.1%
Alector, Inc.ALEC
$69.05M
+12.3%
scPharmaceuticals Inc.SCPH
$49.97M
+107.8%

Gross Margin (Latest Quarter)

Lyell Immunopharma, Inc.LYEL
100.0%
+0.0pp
Voyager Therapeutics, Inc.VYGR
100.0%
+0.0pp
Alector, Inc.ALEC
100.0%
+0.0pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
ANNX$725.94M-4.4-92.3%11.8%
LYEL$504.76M-1.3-96.7%10.9%
VNDA$441.45M-5.2-16.8%1.0%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
N/M
Revenue Volatile
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Mar 9, 2026
|
EPS:-$0.13
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 10, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.12-60.0%
    N/A

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 6, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.14-58.8%
    N/A

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 7, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.24-40.0%
    N/A

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Mar 10, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-1.31+22.0%
    N/A

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 6, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.30-23.1%
    N/A

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 8, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.34-24.4%
    N/A

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 14, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.40-7.0%
    N/A

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Mar 18, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-1.68+39.1%
    N/A